Outcomes and Prognostic Factors of Cirrhotic Patients with Hepatocellular Carcinoma After Radical Major Hepatectomy
Overview
Authors
Affiliations
Background: Radical major hepatectomy (RMH) has been suggested as one of main options for cure of large/advanced hepatocellular carcinoma (HCC). However, its operative risk remains high and its effectiveness is still controversial, especially for patients with liver cirrhosis. The present study aims to investigate short- and long-term outcomes and to identify prognostic factors for cirrhotic patients with HCC after RMH.
Materials And Methods: Prospectively collected clinicopathological data of 81 consecutive cirrhotic HCC patients who underwent RMH were reviewed retrospectively. The Kaplan-Meier method was adopted for evaluating long-term survival. Prognostic factors were identified by univariate and multivariate analyses.
Results: After RMH, perioperative mortality, overall morbidity, and life-threatening morbidity were 1.2%, 24.7%, and 12.3%, respectively. Overall and disease-free 5-year survival rates were 39.4% and 28.1%, respectively. Univariate analysis showed that presence of portal vein tumor thrombosis (PVTT) and satellite nodules, late TNM staging, high Edmondson-Steiner grading, and blood transfusion was associated with worsened prognosis. Of them, Edmondson-Steiner grading was identified as the sole independent prognostic factor for both overall and disease-free survival by multivariate analysis, whereas blood transfusion and the presence of PVTT independently predicted unfavorable overall or disease-free survival, respectively.
Conclusions: These data indicated that RMH was safe and appeared to be effective in treating cirrhotic patients with HCC. Some tumor-related and clinical variables influenced long-term outcome of these patients after RMH.
Lv T, Liu F, Jin Y, Hu H, Ma W, Li F J Gastrointest Surg. 2023; 27(12):2983-3000.
PMID: 37932594 DOI: 10.1007/s11605-023-05860-0.
Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms.
Hytiroglou P, Bioulac-Sage P, Theise N, Sempoux C Cancers (Basel). 2022; 14(15).
PMID: 35954333 PMC: 9367411. DOI: 10.3390/cancers14153670.
Masior L, Grat M, Grat K, Krasnodebski M, Wronka K, Stypulkowski J Ann Transplant. 2020; 25:e923665.
PMID: 33079923 PMC: 7552880. DOI: 10.12659/AOT.923665.
Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
Rastogi A World J Gastroenterol. 2018; 24(35):4000-4013.
PMID: 30254404 PMC: 6148422. DOI: 10.3748/wjg.v24.i35.4000.
Ogihara Y, Kitazume Y, Iwasa Y, Taura S, Himeno Y, Kimura T Br J Radiol. 2017; 91(1084):20170728.
PMID: 29271235 PMC: 5965986. DOI: 10.1259/bjr.20170728.